Lördag 23 November | 04:35:37 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Chordate Medical Holding

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-05-23 08:30 Kvartalsrapport 2025-Q1
2025-05-21 - Årsstämma
2025-02-28 08:30 Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-08-29 - Split CMH 500:1
2024-05-24 - Kvartalsrapport 2024-Q1
2024-05-20 - X-dag ordinarie utdelning CMH 0.00 SEK
2024-05-15 - Årsstämma
2024-03-22 - Bokslutskommuniké 2023
2024-01-26 - Extra Bolagsstämma 2024
2023-11-01 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-04-14 - X-dag ordinarie utdelning CMH 0.00 SEK
2023-02-28 - Bokslutskommuniké 2022
2022-12-13 - Extra Bolagsstämma 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-05-27 - Kvartalsrapport 2022-Q1
2022-04-26 - X-dag ordinarie utdelning CMH 0.00 SEK
2022-04-25 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-10-25 - Kvartalsrapport 2021-Q3
2021-10-05 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-05-27 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning CMH 0.00 SEK
2021-04-15 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-18 - Extra Bolagsstämma 2020
2020-08-07 - Kvartalsrapport 2020-Q2
2020-04-29 - Kvartalsrapport 2020-Q1
2020-04-24 - X-dag ordinarie utdelning CMH 0.00 SEK
2020-04-23 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-11 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-24 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning CMH 0.00 SEK
2019-05-09 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-25 - Kvartalsrapport 2018-Q1
2018-04-27 - X-dag ordinarie utdelning CMH 0.00 SEK
2018-04-26 - Årsstämma
2018-02-28 - Bokslutskommuniké 2017
2017-10-31 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-04-28 - Kvartalsrapport 2017-Q1
2017-04-20 - X-dag ordinarie utdelning CMH 0.00 SEK
2017-04-19 - Årsstämma
2017-02-10 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Chordate Medical Holding är ett medicintekniskt bolag som har utvecklat, patenterat och CE-märkt en nervmodulerande behandlingsteknik för kronisk migrän och kronisk nästäppa (rinit), Kinetic Oscillation Stimulation (K.O.S). Bolaget säljer produkter till behandlande kliniker på utvalda europeiska marknader, Israel samt Saudiarabien, med målsättningen att öka närvaron på den globala marknaden.
Chordate Medical Receives First Order for Ozilia Migraine Treatment from Saudi Arabia
2024-09-30 14:15:00

Chordate Medical has received its first order for the Ozilia migraine treatment from Janin Medical, the company's distributor in Saudi Arabia. The order is for two Ozilia systems that can be used for migraine treatment as soon as marketing approval for Ozilia's migraine indication is obtained in the country.

"Following the success of Ozilia for chronic rhinitis in Saudi Arabia, it is encouraging to see results also in the migraine segment. This order is a result of hard work by Janin Medical, who are also working on securing the registration for the migraine treatment as soon as possible," says Anders Weilandt, CEO of Chordate.

Saudi Arabia and the rest of the Gulf region have long been among Chordate's priority markets to demonstrate proof of concept, and Ozilia has been used for a longer period by several private hospitals for rhinitis treatment.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate Medical Receives First Order for Ozilia Migraine Treatment from Saudi Arabia

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden